Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427342 | 0.81 | KDM4E (0.43) | KDM4ENPC1RAB9APKMHDAC1 | |
| SCHEMBL29373485 | 0.81 | TLR9 (0.47) | KDM4ENPC1RAB9APKMTLR9 | |
| SCHEMBL22129495 | 0.81 | TLR9 (0.52) | KDM4ENPC1RAB9APKMTLR9 | |
| SCHEMBL31000102 | 0.81 | NPC1 (0.47) | KDM4ENPC1RAB9APKMTLR9 | |
| SCHEMBL753696 | 0.81 | NPC1 (0.47) | KDM4ENPC1RAB9APKMTLR9 | |
| SCHEMBL15004635 | 0.80 | HDAC1 (0.41) | KDM4ENPC1RAB9APKMHDAC1 | |
| SCHEMBL13050350 | 0.78 | TLR9 (0.46) | KDM4ENPC1RAB9APKMTLR9 | |
| SCHEMBL13080337 | 0.78 | METTL3 (0.49) | KDM4ENPC1RAB9APKMTLR9 | |
| SCHEMBL28539546 | 0.78 | KDM4E (0.74) | KDM4ENPC1RAB9APKMTLR9 | |
| SCHEMBL24760174 | 0.78 | HDAC1 (0.37) | KDM4ENPC1RAB9APKMTLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-20150322069-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-11-12 | — | — | US | disclosed |
| US-8946222-B2 | Phenoxymethyl heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130143888-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHAMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322069-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | PDE3A, PDE2A, PDE5A | KDM4E 559/4885NPC1 2094/4885RAB9A 1008/4885 |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | KDM4E 483/4885NPC1 2452/4885RAB9A 2608/4885 |
| US-20130143888-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | PDE3A, PDE2A, PDE5A | KDM4E 559/4885NPC1 2094/4885RAB9A 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.